Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biased Signaling as Allosteric Probe Dependence: Everything Old Is New Again.

Biochemistry·2026
Same author

Therapeutic implications of target residence time.

Current opinion in structural biology·2026
Same author

Structure-based design of an opioid receptor modulator for enhanced morphine analgesia.

Science advances·2026
Same author

Differential Effects of Sodium on Agonist-Induced Conformational Transitions and Signaling at μ and κ Opioid Receptors.

Biochemistry·2025
Same author

Agonism and Biased Signaling.

Handbook of experimental pharmacology·2025
Same author

Differential effects of sodium on agonist-induced conformational transitions and signaling at μ and κ opioid receptors.

bioRxiv : the preprint server for biology·2025
Same journal

PKM and the maintenance of memory.

F1000 biology reports·2013
Same journal

Cytokines in chronic respiratory diseases.

F1000 biology reports·2013
Same journal

Protein flexibility, not disorder, is intrinsic to molecular recognition.

F1000 biology reports·2013
Same journal

The case for intrinsically disordered proteins playing contributory roles in molecular recognition without a stable 3D structure.

F1000 biology reports·2013
Same journal

Is perceptual learning associated with changes in a sensory region?

F1000 biology reports·2012
Same journal

Molecular evolution and genetics of postzygotic reproductive isolation in plants.

F1000 biology reports·2012
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Biased agonism.

Terry Kenakin1

  • 1Department of Biological Reagents and Assay Development, Molecular Discovery, GlaxoSmithKline Research and Development 5 Moore Drive, Research Triangle Park, NC 27709 USA. terry.p.kenakin@gsk.com

F1000 Biology Reports
|October 16, 2010
PubMed
Summary
This summary is machine-generated.

Biased agonists reveal that seven-transmembrane receptors activate specific signaling pathways, challenging the traditional model. This discovery opens avenues for targeted therapeutic applications by selectively modulating cellular responses.

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Experiment Videos

Last Updated: Jun 8, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Area of Science:

  • Cellular signaling
  • Molecular pharmacology
  • Receptor biology

Background:

  • Seven-transmembrane receptors (7TMRs) traditionally activate multiple cellular pathways uniformly.
  • Emerging data indicate agonists can selectively activate specific 7TMR-linked pathways.

Purpose of the Study:

  • To discuss the concept of biased agonism in 7TMR signaling.
  • To explore the implications of biased agonism for understanding receptor activation.
  • To review potential therapeutic applications of biased agonists.

Main Methods:

  • Review of existing scientific literature and data on 7TMR signaling.
  • Analysis of agonist-biased signaling profiles.
  • Discussion of theoretical frameworks for biased agonism.

Main Results:

  • The traditional model of uniform pathway activation by agonists is insufficient.
  • Certain agonists selectively activate a subset of pathways linked to 7TMRs, termed 'biased agonists'.
  • Evidence supports the mechanism of biased agonism across various 7TMR systems.

Conclusions:

  • Biased agonism represents a significant paradigm shift in understanding 7TMR function.
  • Selective pathway activation by biased agonists offers novel therapeutic strategies.
  • Further research into biased agonism could lead to more precise drug development.